|
|
Parkveien 53 B
Oslo, NO-0256 Norway
phone:+47 24 11 09 50
fax:(47) 24 11 09 51
|
|
| Symbol |
CLAVIS |
| Exchange |
OSL |
| Founded |
2001 |
| Employees |
|
|
|
| www.clavispharma.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Using lipid vector technology to develop pharmaceuticals. |
|
| Management |
| Geir Christian Melen, Chief Executive Officer; Ole Henrik Eriksen, Chief Operating Officer; Gunnar Manum, Chief Financial Officer; Jan Alfheim, Chief Business Officer; Bo I. Nilsson, Chief Medical Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| elacytarabine, gemcitabine, leukaemia, intravenous, myelodysplastic |
|
|
|
| Description |
|
Clavis Pharma develops new and superior pharmaceuticals by leveraging the potential of its Lipid Vector Technology, LVT. |
|
| Products / Services |
Clavis lead development candidate, CP-4055 is an LVT derivative of cytarabine (Ara-C), an approved cytotoxic drug used to treat blood cancers. Clavis second development candidate in oncology, CP-4126, is an LVT derivative of gemcitabine (Gemzar). CP-4010 and CP-4018 are LVT derivatives of acyclovir and ganciclovir respectively. Acyclovir (Zovirax) is a key drug in the treatment of herpes and shingles while Ganciclovir (Cytovene) is a potent drug used for the treatment of cytomegalovirus.
|
|
| Technology / Differentiation |
| Clavis Pharma's LVT implies chemical binding of certain fatty acids to pharmaceutical agents, thereby creating new chemical entities with improved biological properties such as increased cellular uptake, reduced toxicity and slow release of the active compound. The company has demonstrated LVT's potential to improve drug performance and to open new indications for existing pharmaceuticals in a variety of therapeutic areas such as cancer and viral diseases. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
